Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Pfizer Abrilada, biosimilar to Humira gets USFDA nod for multiple inflammatory conditions

      Pfizer Abrilada, biosimilar to Humira gets USFDA nod for multiple inflammatory conditions

      Farhat Nasim20 Nov 2019 12:44 PM IST
      New Delhi: Pfizer Inc. recently announced the United States (U.S.) Food and Drug Administration (USFDA) has approved ABRILADA (adalimumab-afzb), as a...
      Pharmacists to protest at Jantar Mantar against amendment of Schedule K of Drugs and Cosmetics Act

      Pharmacists to protest at Jantar Mantar against amendment of Schedule K of Drugs and Cosmetics Act

      Farhat Nasim18 Nov 2019 2:55 PM IST
      New Delhi: The Indian Pharmacist Association (IPA) has decided to conduct a protest on November 29 at Jantar Mantar against the recent draft to amend...
      Zydus Cadila gets tentative USFDA nod for arthritis drug Apremilast

      Zydus Cadila gets tentative USFDA nod for arthritis drug Apremilast

      Farhat Nasim18 Nov 2019 11:08 AM IST
      The company has received the tentative approval from the United States Food and Drug Administration (USFDA) to market generic Apremilast tablets in...
      Unichem Labs receives US regulatory nod for generic version of Buspar tablets

      Unichem Labs receives US regulatory nod for generic version of Buspar tablets

      Farhat Nasim18 Nov 2019 10:00 AM IST
      Unichem Labs' Buspirone Hydrochloride tablets are a generic version of Bristol-Myers Squibb Company's Buspar tablets in the same strengths.New Delhi:...
      JnJ directed to pay USD 465 million for fueling opioid epidemic via deceptive marketing of painkillers

      JnJ directed to pay USD 465 million for fueling opioid epidemic via deceptive marketing of painkillers

      Farhat Nasim18 Nov 2019 9:45 AM IST
      New Delhi: An Oklahoma judge on Friday said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the...
      NPPA fixes retail price of 12 combo drugs including Aspirin, Atorvastatin, Metformin; Details

      NPPA fixes retail price of 12 combo drugs including Aspirin, Atorvastatin, Metformin; Details

      Farhat Nasim17 Nov 2019 1:08 PM IST
      New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
      You cannot discontinue critical medicines without Prior Notice: NPPA tells Abbott, Bayer Zydus Pharma, Sanofi

      You cannot discontinue critical medicines without Prior Notice: NPPA tells Abbott, Bayer Zydus Pharma, Sanofi

      Farhat Nasim16 Nov 2019 1:04 PM IST
      Abbott Healthcare has near monopoly (around 98% market share) for these critical medicines for leprosy, Bayer Zydus Pharma has about a 12% market...
      Aurobindo Pharma gets 14 USFDA observations for Pashamylaram facility

      Aurobindo Pharma gets 14 USFDA observations for Pashamylaram facility

      Farhat Nasim15 Nov 2019 12:13 PM IST
      The US Food and Drug Administration (USFDA) inspected company's Unit IV, a general injectable formulation manufacturing facility situated at...
      Healthcare startup ekincare raises over Rs 25 crore in Series A funding

      Healthcare startup ekincare raises over Rs 25 crore in Series A funding

      Farhat Nasim14 Nov 2019 10:10 AM IST
      New Delhi: Health benefits start-up ekincare on Wednesday said it has raised USD 3.6 million (about 25.8 crores) in a funding round from investors...
      Merck licenses CRISPR gene-editing technology to Evotec

      Merck licenses CRISPR gene-editing technology to Evotec

      Farhat Nasim14 Nov 2019 9:15 AM IST
      New Delhi: Merck, recently announced that it has signed a license agreement providing Evotec SE access to Merck's foundational CRISPR intellectual...
      NPPA fixes retail price of 14 drug formulations; Details

      NPPA fixes retail price of 14 drug formulations; Details

      Farhat Nasim13 Nov 2019 11:23 AM IST
      New Delhi: Through a recent notification, the apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the...
      JnJ blockbuster drug Remicade losing ground in Quebec health plan despite court victory

      JnJ blockbuster drug Remicade losing ground in Quebec health plan despite court victory

      Farhat Nasim13 Nov 2019 9:47 AM IST
      The plan's administrator stopped covering Remicade, JnJ unit Janssen's version of the drug infliximab, for some new patients in February 2017, in...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok